Answers are grounded in this paper and cite their sources.
While hypothermic machine perfusion reduces delayed graft function (DGF) after kidney transplantation, its long-term benefits in controlled donation after circulatory death (DCD) are uncertain in real-world practice. We evaluated whether perfusion improves 5-year death-censored graft survival compared to static cold storage in DCD by benchmarking outcomes against those of donation after brain death (DBD). After analyzing the United Network for Organ Sharing and Swiss Transplant Cohort Study registries, we created a 1:1 propensity-score-matched cohort to balance baseline characteristics. Among 44,552 DCD recipients (34,739 with perfusion; 9,813 with cold storage) and 180,898 DBD controls, the matched 5-year death-censored graft survival rate was 84.8% with perfusion versus 87.4% with cold storage (hazard ratio 1.08; P = 0.19). Perfusion significantly reduced the rate of DGF (35.7% vs. 44.9%; P < 0.001), while the rates of primary nonfunction and acute rejection were comparable. Both DCD groups achieved long-term outcomes equivalent to those of the DBD cohort. In conclusion, while machine perfusion confers a substantial early reduction in delayed graft function, static cold storage continues to deliver excellent 5-year graft survival. Both strategies yield excellent long-term outcomes comparable to those of DBD transplants. Crucially, these findings support expanding DCD programs to include older donors as a vital strategy to increase transplantation rates and reduce waitlist mortality. To optimize outcomes in these older DCD grafts, clinicians should aim to limit donor comorbidity, keep total ischemia time below 12–15 h, and utilize continuous rather than end-ischemic machine perfusion whenever logistically feasible.
No takes yet. Share an insight, caveat, or question.
Papageorgiou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: